Propionyl-L-carnitine therapy: Effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease

Kidney and Blood Pressure Research

Volumn 29, Issue 2, 2006, Pages 100-107

  Signorelli, Salvatore Santo ^a,c   Fatuzzo, Pasquale ^a   Rapisarda, Francesco ^a   Neri, Sergio ^a   Ferrante, Margherita ^b   Conti, Gea Oliveri ^b   Fallico, Roberto ^b   Di Pino, Luigi ^a   Pennisi, Giuseppe ^a   Celotta, Gabriella ^a   Anzaldi, Massimiliano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c NONE   (Italy)

Author keywords

End stage renal disease; L Carnitine; Peripheral arterial disease

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DROMOS; ENDOTHELIN 1; HOMOCYSTEINE; PLACEBO; PROPIONYLCARNITINE; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANKLE; BRANCHIAL REGION; CARNITINE; DOUBLE-BLIND METHOD; ENDOTHELIN-1; HOMOCYSTEINE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; PERIPHERAL VASCULAR DISEASES; PLACEBOS; RENAL DIALYSIS;

EID: 33747076071     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094363     Document Type: Article

References (48)

1. Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9(suppl 12):S24-S30.
2. Levin A: Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002;80:35-38.
3. London GM: Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003;16:85-94.
4. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-1615.
5. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35(suppl 1):S117-S131.
6. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall MJ, Townend JN, Wheeler DC: Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001;38:537-546.
7. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
8. Agapitov AV, Haynes WG: Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002;3:1-15.
9. Lariviere R, Lebel M: Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003;81:607-621.
10. Rohmeiss P, Birck R, Braun C, Kirchengast M, van der Woude FJ: Targets for endothelin in the diseased kidney: clues for therapeutic intervention. Exp Nephrol 1999;7:1-10.
11. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, London GM: Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 1998;13:375-383.
12. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
13. Harrison DG: Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994; 89(suppl 1):87-102.
14. Darius H, Pittrow D, Haberl R, Trampisch HJ, Schuster A, Lange S, Tepohl HG, Allenberg JR, Diehm C: Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest 2003;33:751-757.
15. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
16. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2678.
17. Kang SS, Wong PW, Malinow MR: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-298.
18. Klahr S: Mechanisms of progression of chronic renal damage. J Nephrol 1999;12(suppl 2):S53-S62.
19. Levey AS, Eknoyan G: Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999;14:828-833.
20. Kundhal K, Lok CE: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005;101:c47-c52.
21. Lamar Welch VL, Casper M, Greenlund K, Zheng ZJ, Giles W, Rith-Najarian S: Prevalence of lower extremity arterial disease defined by the ankle-brachial index among American Indians: the Inter-Tribal Heart Project. Ethn Dis 2002;12:S1-63-67.
22. O'Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004;109:320-323.
23. Rose GA: The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962;27:645-658.
24. Leskinen Y, Salenius JP, Lehtimaki T, HuhtaIa H, Saha H: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002;40:472-479.
25. Ikizler TA: Role of nutrition for cardiovascular risk reduction in chronic kidney disease patients. Adv Chronic Kidney Dis 2004;11:162-171.
26. Violi F, Loffredo L, Mancini A, Marcoccia A: Antioxidants in peripheral arterial disease. Curr Drug Targets 2003;4:651-655.
27. Cittanti C, Colamussi P, Giganti M, Orlandi C, Uccelli L, Manfrini S, Azzena G, Piffanelli A: Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. Eur J Nucl Med 1997;24:762-766.
28. Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M, Matarazzo A, Marcialis A: Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991;84:1490-1495.
29. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP: Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-353.
30. Signorelli SS, Malaponte G, Di Pino L, Digrandi D, Pennisi G, Mazzarino MC: Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration. Pharmacol Res 2001;44:305-309.
31. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C: Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004;1033:79-91.
32. Sayed-Ahmed MM, Shouman SA, Rezk BM, Khalifa MH, Osman AM, El-Merzabani MM: Propionyl-L-carnitine as potential protective agent against Adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria. Pharmacol Res 2000;41:143-150.
33. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A: Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-1028.
34. Hurot JM, Cucherat M, Haugh M, Fouque D: Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002;13:708-714.
35. Labonia WD: L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995;26:757-764.
36. Vlassopoulos DA, Hadjiyannakos DK, Anogiatis AG, Evageliou AE, Santikou AV, Noussias CV, Papandreou PT, Hadjiconstantinou VE: Carnitine action on red blood cell osmotic resistance in hemodialysis patients. J Nephrol 2002;15:68-73.
37. Taute BM, Taute R, Heins S, Behrmann C, Podhaisky H: Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int Angiol 2004;23:35-40.
38. Loncar R, Hrboka V, Tabakovic-Loncar V, Ostojic Z, Deussen A: Screening of plasma homocysteine in peripheral arterial disease. Ann Med 2001;33:48-54.
39. Dashwood MR, Jagroop IA, Gorog DA, Bagger JP: A potential role for endothelin-1 in peripheral vascular disease. J Cardiovasc Pharmacol 2000;36(suppl 1):S93-S94.
40. Sener G, Eksioglu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N, Yegen BC: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 2006;22:47-60.
41. Sener G, Paskaloglu K, Satiroglu H, Alican I, Kacmaz A, Sakarcan A: L-Carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol 2004;43:698-705.
42. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A: Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-622.
43. Miller B, Ahmad S: A review of the impact of L-carnitine therapy on patient functionality in maintenance hemodialysis. Am J Kidney Dis 2003;41(suppl 4):S44-S48.
44. Steiber AL, Weatherspoon LJ, Spry L, Davis AT: Serum carnitine concentrations correlated to clinical outcome parameters in chronic hemodialysis patients. Clin Nutr 2004;23:27-34.
45. Pola P, De Martini D, Gerardino L, De Rossi S, Tondi P: The action of propionyl-L-carnitine on the vasal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study. Drugs Exp Clin Res 1992;18:343-348.
46. Pola P, Flore R, Tondi P, Nolfe G: Rheological activity of propionyl-L-carnitine. Drugs Exp Clin Res 1991;17:191-196.
47. Hulsmann WC, Dubelaar ML: Carnitine requirement of vascular endothelial and smooth muscle cells in imminent ischemia. Mol Cell Biochem 1992;116:125-129.
48. Spagnoli LG, Orlandi A, Marino B, Mauriello A, De Angelis C, Ramacci MT: Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis 1995;114:29-44.